Stockscreener 앱 받기
21.70
23.00%
-6.48
시간 외 거래:
22.50
0.80
+3.69%
Cg Oncology Inc 주식(CGON)의 최신 뉴스
Here Are Reasons Why Cg Oncology Inc (NASDAQ: CGON) Is A Great Choice Now - Stocksregister
CG Oncology Jumps 25% on Positive Trial Results - Orange County Business Journal
CG Oncology, Inc. (NASDAQ:CGON) Given Consensus Recommendation of “Buy” by Analysts - Defense World
CG Oncology, Inc. (NASDAQ:CGON) Shares Purchased by Invesco Ltd. - Defense World
CG Oncology initiated with an Overweight at JPMorgan - TipRanks
CGON Stock: JP Morgan Initiates Coverage with Overweight Rating - GuruFocus
JPMorgan Initiates Coverage on CG Oncology With Overweight Rating, $41 Price Target - marketscreener.com
CGON: JPMorgan Starts Coverage with Overweight Rating and $41 Ta - GuruFocus
CG Oncology (NASDAQ:CGON) Reaches New 1-Year Low After Insider Selling - Defense World
Why CG Oncology, Inc. (CGON) Surged on Monday - MSN
CG Oncology, Inc. (CGON) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance
Cg Oncology Inc’s (CGON) Stock Is Harder To Predict Than You Think - Stocksregister
SUO-CTC and CG Oncology Announce the 2025 Award Recipients for the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award - The Manila Times
CG Oncology, Inc. (NASDAQ:CGON) Shares Bought by Wells Fargo & Company MN - Defense World
A look into Cg Oncology Inc (CGON)’s deeper side - Sete News
Stock Performance Spotlight: Cg Oncology Inc (CGON) Ends the Day at 26.94, Down by -3.68 - DWinneX
Could Cg Oncology Inc (NASDAQ: CGON) Be The Biggest Winner? - Marketing Sentinel
Barclays PLC Acquires 10,737 Shares of CG Oncology, Inc. (NASDAQ:CGON) - Defense World
CG Oncology's Bladder Cancer Drug Impresses InvestorsHere's Why - AOL.com
Cg Oncology Inc [CGON] Stock sold by Insider POST LEONARD E for $28000.0 - knoxdaily.com
CG Oncology, Inc. (CGON) Surges 25.0%: Is This an Indication of Further Gains? - MSN
TD Cowen Sticks to Its Buy Rating for CG Oncology, Inc. (CGON) - The Globe and Mail
CG Oncology (NASDAQ:CGON) Given Overweight Rating at Cantor Fitzgerald - Defense World
CG Oncology’s (CGON) Buy Rating Reaffirmed at HC Wainwright - Defense World
CG Oncology shares jump on positive clinical trial data for cancer drug - Mugglehead Magazine
CG Oncology Stock (CGON) Surges 25% As Cancer Drug Shows Remarkable Results - TipRanks
J&J Looks To Overcome Drug-Delivery Limitations In Bladder Cancer With TAR-200 - insights.citeline.com
CG Oncology (CGON) Surges 25%: What Drove the Dramatic Stock Move? - Wealth Daily
Crude Oil Down 2%; Roper Technologies Increases 2025 Outlook - Benzinga
CG Oncology’s Blistering Rally: What You Need to Know - RagingBull
Cantor Fitzgerald maintains CG Oncology stock with $75 target - Investing.com Australia
CG Oncology Reports Durable Responses for Cretostimogene in Bladder Cancer Treatment; Shares Rise - marketscreener.com
Biohaven gets an up to $600M investment; Prilenia, Ferrer make a deal in Europe - Endpoints News
CG Oncology Rockets On Its Johnson & Johnson-Rivaling Cancer Drug - inkl
This Small Biotech Rival To J&J Just Rocketed 44% - Investor's Business Daily
Cantor Fitzgerald maintains CG Oncology stock with $75 target By Investing.com - Investing.com India
Dow Jumps Over 150 Points; Domino's Pizza Posts Upbeat Earnings - Benzinga
Cg Oncology Inc (CGON) did well last session? - uspostnews.com
CG Oncology (CGON) Announces Phase 3 Trial Results Discussion - GuruFocus
Contrasting CG Oncology (CGON) & Its Rivals - Defense World
CGON Shows Promising Results in Bladder Cancer Study | CGON Stoc - GuruFocus
CGON: Insights on Phase 3 BOND-003 Trial Results for Bladder Can - GuruFocus
CG Oncology announces Phase 3 BOND-003 data presented at AUA meeting - TipRanks
CG Oncology Reports Promising 24-Month Efficacy and Safety Data for Cretostimogene Monotherapy in Patients with High-Risk Non-Muscle Invasive Bladder Cancer - Nasdaq
CG Oncology Announces Best-In-Disease Durability Data In Bond-003 Cohort C & Promising Early Signal In Cohort P For Cretostimogene Grenadenorepvec - TradingView
CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting - The Globe and Mail
CG Oncology Bladder Cancer Drug Shows 42% Complete Response at 24 Months | CGON Stock News - Stock Titan
CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025 - The Manila Times
CG Oncology's Breakthrough Phase 3 Bladder Cancer Treatment Data: What The AUA Plenary Will Reveal - Stock Titan
Daily Market Movement: Cg Oncology Inc (CGON) Sees a 0.34 Increase, Closing at 20.48 - DWinneX
Taking a Closer Look At Cg Oncology Inc (CGON) Following Its Recent Trade - knoxdaily.com
CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates - ADVFN
Cg Oncology Inc (CGON)’s stock price range in the last year - uspostnews.com
CG Oncology, Inc. (NASDAQ:CGON) Shares Acquired by JPMorgan Chase & Co. - Defense World
CG Oncology (NASDAQ:CGON) Coverage Initiated at Scotiabank - Defense World
Geode Capital Management LLC Has $33.18 Million Stock Position in CG Oncology, Inc. (NASDAQ:CGON) - Defense World
CG Oncology initiated with a Sector Perform at Scotiabank - TipRanks
Scotiabank Initiates Coverage of CG Oncology (CGON) with Sector Perform Recommendation - Nasdaq
Scotiabank Initiates CG Oncology at Sector Perform With $23 Price Target - marketscreener.com
CG Oncology (CGON) vs. Its Competitors Financial Comparison - Defense World
Midday Stock Roundup: BJ’s Restaurants Beats Estimates - Orange County Business Journal
KLP Kapitalforvaltning AS Takes $100,000 Position in CG Oncology, Inc. (NASDAQ:CGON) - Defense World
5.24%
자본화:
|
볼륨(24시간):